T. I. Ionova¹, B. V. Afanasiev², A. A. Amdiev³, M. I. Andrievskikh⁴, E. A. Baryakh⁵, Eu. V. Vasiliev⁶, M. V. Volkov⁷, E. M. Volodicheva⁸, V. V. Ivanov⁹, O. V. Kaverina¹⁰, K. D. Kaplanov¹¹, T. Yu. Klitochenko¹¹, V. I. Kurakin¹², D. G. Lazareva¹⁰, O. G. Larionova⁷, K. V. Lepik², I. B. Lysenko¹³, R. I. Minullina¹⁴, O. V. Mironov¹⁵, E. N. Misyurina⁵, N. B. Mikhailova², N. Eu. Mochkin¹⁶, T. P. Nikitina¹, Iu. S. Osipov⁹, T. S. Petrova¹⁴, N. M. Porfirieva¹, O. A. Rykavitsyn¹⁷, R. N. Safin¹⁴, P. I. Simashova¹⁷, E. G. Smirnova¹⁶, N. A. Trenina¹², N. V. Fadeeva⁴, G. N. Husainova¹⁴, V. L. Chang¹⁵, T. V. Shelekhova¹⁸, D. G. Sherstnev¹⁸

Quality of life in patients with relapsed/refractory Hodgkin lymphoma receiving treatment with brentuximab vedotin in the real world practice

¹MULTINATIONAL CENTER FOR QUALITY OF LIFE RESEARCH, SAINT-PETERSBURG

²RAISA GORBACHEVA MEMORIAL RESEARCH INSTITUTE OF CHILDREN ONCOLOGY, HEMATOLOGY AND TRANSPLANTATION, I. P. PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY, MINISTRY OF HEALTH OF RUSSIA, SAINT-PETERSBURG

³V. M. EFETOV CRIMEAN REPUBLICAN ONCOLOGY CENTER, SIMFEROPOL

⁴CHELYABINSK REGIONAL CLINICAL CENTER OF ONCOLOGY AND NUCLEAR MEDICINE, CHELYABINSK

⁵CITY CLINICAL HOSPITAL № 52, MOSCOW

⁶REGIONAL CLINICAL HOSPITAL, KRASNOYARSK

⁷PRIMORSKY REGIONAL ONCOLOGIC CENTER, VLADIVOSTOK

⁸TULA REGIONAL CLINICAL HOSPITAL, TULA

⁹V.A. ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE, SAINT-PETERSBURG

¹⁰ALTAI REGIONAL ONCOLOGY CENTRE, BARNAUL

¹¹VOLGOGRAD REGIONAL CLINICAL ONCOLOGY DISPENSARY, VOLGOGRAD

¹²CLINICAL ONCOLOGICAL CENTER, OMSK

¹³ROSTOV RESEARCH INSTITUTE OF ONCOLOGY, ROSTOV-ON-DON

¹⁴REPUBLICAN CLINICAL ONCOLOGY CENTER OF THE MINISTRY OF HEALTH OF THE REPUBLIC OF TATARSTAN, KAZAN

¹⁵TAMBOV REGIONAL ONCOLOGICAL CLINICAL CENTER, TAMBOV

¹⁶N. I. PIROGOV NATIONAL MEDICAL SURGICAL CENTER, MOSCOW

¹⁷N. N. BURDENKO PRINCIPAL MILITARY CLINICAL HOSPITAL, MOSCOW

¹⁸DEPARTMENT OF OCCUPATIONAL PATHOLOGY, HEMATOLOGY AND CLINICAL PHARMACOLOGY, V.I. RASYMOVSKY SARATOV STATE MEDICAL UNIVERSITY, SARATOV

The analysis of the data of multicenter observational study «Patient-reported and clinical outcomes in adults with relapsed or refractory Hodgkin's lymphoma receiving brentuximab vedotin: a multicenter, prospective, observational study in a real world setting» has been reported. Patients with relapsed/refractory Hodgkin lymphoma (HL) have to be included in the study before ?3 line of treatment with brentuximab vedotin (BV) start. Clinical response, tolerability, quality of life (QoL) and symptoms after 3 mos of BV treatment in the group of 55 patients have been analyzed. Treatment response was assessed using RECIST criteria v. 1.0. Adverse events (AEs) were assessed in accordance with NCI CTCAE v. 4.03. For QoL assessment pts filled out RAND SF-36, for symptom assessment — ESAS questionnaire before treatment with BV and at 3 mo after BV treatment start; also patients filled out PGIC scale for self-assessment of changes in their health at 3 mo after BV treatment start. For QoL analysis paired t-test, Mann–Whitney test, Wilcoxon test and ? 2 were used. Before BV treatment start QoL was dramatically worsened for all SF-36 scales (p<0,05); the most worsening was revealed for role functioning, vitality and general health. All the patients experienced symptoms, 83.3 % pts had moderate-to-severe symptoms. After 3 mos of BV treatment objective response was registered in 55 % pts, among them 27.5 % had complete response. Adverse events of grade I–II were reported in 8 pts (20 %) and were consistent with known toxicities. During BV treatment meaningful QoL and symptom improvement was revealed almost in half of patients. Evaluation of BV treatment outcomes both from physician's and patient's perspective may provide unique information which will be helpful in decision making for patients with RR HL.